Patents Assigned to Trinity Therapeutics, Inc.
  • Methods for inhibiting immune complex formation in a subject
    Patent number: 10179803
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 15, 2019
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • Compositions for inhibiting immune complex formation in a subject
    Patent number: 9447145
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: September 20, 2016
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome
    Patent number: 8815813
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, as well as methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation in viral infection, are described. For example, polypeptides and other compounds can be used to inhibit binding of DF-associated, immune-complexed IgG anti-DF viron(s) or DV viral antigens to F?R, ADE of DF/DHF/DSS infections by inhibition of DF viral antigen binding to immune complexed IgG, F?R and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: August 26, 2014
    Assignee: Trinity Therapeutics, Inc.
    Inventor: Neil M. Bodie
  • METHODS FOR INHIBITING IMMUNE COMPLEX FORMATION IN A SUBJECT
    Publication number: 20130130987
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Application
    Filed: January 28, 2013
    Publication date: May 23, 2013
    Applicant: TRINITY THERAPEUTICS, INC.
    Inventor: Trinity Therapeutics, Inc.
  • Methods for inhibiting immune complex formation in a subject
    Patent number: 8362202
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: January 29, 2013
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • Methods for inhibiting immune complex formation in a subject
    Patent number: 7786258
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: August 31, 2010
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • Methods for inhibiting immune complex formation in a subject
    Patent number: 7714104
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: May 11, 2010
    Assignee: Trinity Therapeutics, Inc.
    Inventors: Neil M. Bodie, Elliot Altman
  • METHODS FOR INHIBITING IMMUNE COMPLEX FORMATION IN A SUBJECT
    Publication number: 20100113362
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.
    Type: Application
    Filed: January 4, 2010
    Publication date: May 6, 2010
    Applicant: TRINITY THERAPEUTICS, INC.
    Inventors: Neil M. Bodie, Elliot Altman
  • METHODS FOR TREATING IMMUNE MEDIATED NEUROLOGICAL DISEASES
    Publication number: 20090105138
    Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, Immune complexed IgG to IgG F?R binding, and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding. Such compounds may have therapeutic use in treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD).
    Type: Application
    Filed: September 6, 2006
    Publication date: April 23, 2009
    Applicant: TRINITY THERAPEUTICS, INC.
    Inventors: Neil M. Bodie, Renee Bodie, Elliot Altman